Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells

Ex vivo gene editing in T cells and hematopoietic stem/progenitor cells (HSPCs) holds promise for treating diseases. Gene editing encompasses the delivery of a programmable editor RNA or ribonucleoprotein, often achieved ex vivo via electroporation, and when aiming for homology-driven correction of...

Descripción completa

Detalles Bibliográficos
Autores principales: Vavassori, Valentina, Ferrari, Samuele, Beretta, Stefano, Asperti, Claudia, Albano, Luisa, Annoni, Andrea, Gaddoni, Chiara, Varesi, Angelica, Soldi, Monica, Cuomo, Alessandro, Bonaldi, Tiziana, Radrizzani, Marina, Merelli, Ivan, Naldini, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Gene Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644071/
https://www.ncbi.nlm.nih.gov/pubmed/37294917
http://dx.doi.org/10.1182/blood.2022019333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644071/
https://www.ncbi.nlm.nih.gov/pubmed/37294917
http://dx.doi.org/10.1182/blood.2022019333

Ejemplares similares